Clinical considerations in designing trials of vaccines for tuberculosis

Clinical Infectious Diseases

Volumn 30, Issue SUPPL. 3, 2000, Pages

  Glassroth, J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG SCREENING; HUMAN; IMMUNE RESPONSE; MORBIDITY; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; PUBLIC HEALTH; TUBERCULOSIS;

BACTERIAL VACCINES; BCG VACCINE; CLINICAL TRIALS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RESEARCH DESIGN; TUBERCULOSIS, PULMONARY;

EID: 0034464992     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313866     Document Type: Conference Paper

References (8)

1. Vaccines and tuberculosis: The glass remains half empty
2. Alternative projections of mortality and disability by cause, 1990-2020: Global burden of disease study
3. Clinical and roentgenographic spectrum of pulmonary tuberculosis in the adult
4. The radiographic appearance of tuberculosis in patients with the acquired immunodeficiency syndrome (AIDS) and pre-AIDS
5. Pulmonary tuberculosis: CT findings - Early active disease and sequential change with antituberculosis therapy
6. Activity of adenosine deaminase in cerebrospinal fluid for the diagnosis of tuberculous meningitis in adults
7. Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection
8. Increased release of interleukin-1β, interleukin-6 and tumor necrosis factor-γ by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis